




# Systemic Amyloidosis Therapeutic Market Set for Robust Growth Driven by Rising Prevalence of Amyloid



The systemic amyloidosis therapeutic market plays an important role in treating amyloidosis-related diseases which occurs due to accumulation of amyloid protein in organs and tissues. Systemic amyloidosis refers to the diseases associated with extracellular amyloid deposits, which primarily affect the heart, kidneys and liver causing their malfunction. The systemic amyloidosis therapeutic products including drugs and medical devices aid in slowing down or stopping further amyloid deposits in tissues and relieving symptoms.

**The Global [Systemic Amyloidosis Therapeutic Market](#) is estimated to be valued at US\$ 6.19 Billion in 2024 and is expected to exhibit a CAGR of 7.9% over the forecast period 2024-2031.**

Systemic amyloidosis diseases develop when amyloid proteins fold abnormally and deposit in tissues and organs. The main types of systemic amyloidosis are AL amyloidosis caused due to abnormal light chain proteins and AA amyloidosis arising from persistent inflammation. These diseases lead to organ damage and often become fatal if left untreated. The availability of effective systemic amyloidosis therapeutic products helps manage amyloidosis symptoms,

stop amyloid deposits and improve quality of life. The growing prevalence of amyloidosis diseases owing to increasing elderly population base and rising chronic inflammation disorders are major factors boosting the demand for these therapeutics.

### **Key Takeaways**

**Key players operating in the systemic amyloidosis therapeutic market are AstraZeneca, Attralus, Ionis Pharmaceuticals, Prothena Biosciences, Alexion Pharmaceuticals.**

The growing prevalence of amyloidosis diseases especially AL amyloidosis is fueling the demand for systemic amyloidosis therapeutics globally. According to estimates, around 20,000 new AL amyloidosis cases are reported every year in the US alone.

The major pharmaceutical companies are collaborating with biotech firms and undertaking strategic initiatives such as new product launches and geographic expansion to strengthen their presence in the global systemic amyloidosis therapeutic market. For instance, Pfizer is expanding drug access in amyloidosis through partnerships with health authorities in new regions.

### **Market Key Trends**

One of the key trends observed in the systemic amyloidosis therapeutic market is rising demand for RNAi therapeutics for amyloidosis treatment. RNA interference is a novel drug development approach to treat human diseases by silencing specific messenger RNAs (mRNAs) before they are translated into disease-promoting proteins. Currently, Ionis Pharmaceuticals has two RNAi drugs in clinical trials for treating amyloidosis - IONIS-TTR-L Rx and IONIS-ATTR-L Rx which hold promise for improved treatment outcomes. The high specificity, potency and safety profile make RNAi an attractive modality for targeting root causes of amyloid diseases through genetic approach. This trend is likely to gain more momentum in the coming years influencing the systemic amyloidosis therapeutic landscape.

### **Porter's Analysis**

**Threat of new entrants:** High capital requirements for R&D and manufacturing are significant barriers.

**Bargaining power of buyers:** Many large buyers and localized treatment limits buyer power.

**Bargaining power of suppliers:** Suppliers of specialized raw materials and components have some bargaining power.

**Threat of new substitutes:** Research into new treatment modalities pose future threat of substitution.

**Competitive rivalry:** Strong competition in late-stage clinical pipeline development and orphan drug status intensifies rivalry.

The systemic amyloidosis therapeutic market in North America currently holds the largest share in terms of value owing to growing prevalence of amyloidosis disorders, rising healthcare expenditures, and presence of key market players in the region. Europe is the second largest regional market driven by increasing approval of novel therapies.

The systemic amyloidosis therapeutic market in Asia Pacific is expected to exhibit the fastest growth over the forecast period attributed to expanding healthcare infrastructure, growing medical tourism, and rising disposable incomes. Additionally, increasing collaboration between domestic and international market players is enhancing amyloidosis treatment accessibility in emerging Asian economies.

### **What Are The Key Data Covered In This Systemic Amyloidosis Therapeutic Market Report?**

- Market CAGR throughout the predicted period
- Comprehensive information on the aspects that will drive the Systemic Amyloidosis Therapeutic 's growth between 2024 and 2031.
- Accurate calculation of the size of the Systemic Amyloidosis Therapeutic and its contribution to the market, with emphasis on the parent market
- Realistic forecasts of future trends and changes in consumer behaviour
- Systemic Amyloidosis Therapeutic Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
- A complete examination of the market's competitive landscape, as well as extensive information on vendors
- Detailed examination of the factors that will impede the expansion of Systemic Amyloidosis Therapeutic vendors

#### **About Author:**

**Ravina Pandya**, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (<https://www.linkedin.com/in/ravina-pandya-1a3984191>)

#### **\*Note:**

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it